A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

Samuel L Washington 3rd, Alan W Shindel, Samuel L Washington 3rd, Alan W Shindel

Abstract

Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

Keywords: PDE5 inhibitor; daily dosing; on-demand therapy; side effects.

References

    1. NIH Panel on Impotence. NIH Consensus Conference: Impotence. JAMA. 1993;270:83–90.
    1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
    1. Feldman HA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000;30(4):328–338.
    1. Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med. 2007;74(Suppl 3):S30–S37.
    1. Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. J Sex Med. 2009;6(11):3111–3124.
    1. Tsertsvadze A, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650–661.
    1. Carson CC. PDE5 inhibitors: are there differences? Can J Urol. 2006;13(Suppl 1):34–39.
    1. Ljunggren C, Hedelin H, Salomonsson K, Stroberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2008;5:469–475.
    1. Paick JS, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5:946–953.
    1. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med. 2009;6(9):2352–2364. quiz 2365–2366.
    1. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4:1315–1330.
    1. Forgue ST, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280–288.
    1. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002;56:300–304.
    1. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998;159(5):1541–1547.
    1. Porst H, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–125. discussion 125–126.
    1. Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int. 2009;103(10):1392–1395.
    1. Vernet D, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006;3:84–94. discussion 94–95.
    1. Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol. 2003;170:S15–S18. discussion S19.
    1. Costa P, Grivel T, Gehchan N. Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. Patient Prefer Adherence. 2009;3:105–111.
    1. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009;6:2039–2048.
    1. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292–300.
    1. Mirone V, et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol. 2005;47:846–854. discussion 854.
    1. Costa P, et al. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. J Sex Med. 2006;3:1050–1058.
    1. Moncada I, et al. Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries. J Sex Med. 2005;2:668–674.
    1. Buvat J, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled Use vs. On-Demand Regimen Evaluation (SURE) study in 14 European countries. J Sex Med. 2006;3:512–520.
    1. Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2006;108:429–431.
    1. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228–1234.
    1. Rosato E, et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud’s phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J Biol Regul Homeost Agents. 2009;23:23–29.
    1. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–1813.
    1. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16(Suppl 1):S4–S7.
    1. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res. 1999;11:123–132.
    1. Miles CL, et al. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev. 2007:CD005540.
    1. Rosen RC, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
    1. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54:346–351.
    1. Shabsigh R, et al. Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. Int J Impot Res. 2010;22(1):1–8.
    1. Cappelleri JC, et al. Development and validation of the self-esteem and relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004;16:30–38.
    1. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1–52.
    1. Cordell WH, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol. 2009;127:367–373.
    1. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11–S14.
    1. Rosen RC, et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med. 2004;1:193–200.
    1. Francis SH, Morris GZ, Corbin JD. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res. 2008;20:333–342.
    1. Porst H, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351–359.
    1. Donatucci CF, et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin. 2008;24:3383–3392.
    1. Forgue ST, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007;63:24–35.
    1. Kloner RA, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855–1860.
    1. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415–425. discussion 425–427.
    1. Rajfer J, et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007;19:95–103.
    1. Porst H, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008;5:2160–2169.
    1. Hatzichristou D, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138–146.
    1. Porst H, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;56:727–735.
    1. Conaglen HM, Conaglen JV. Investigating women’s preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners’ preference study. J Sex Med. 2008;5:1198–1207.
    1. Rubio-Aurioles E, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009;6:1314–1323.
    1. Seftel AD, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res. 2009;21:240–248.
    1. Althof SE, et al. Impact of tadalafil once daily in men with erectile dysfunction-including a report of the partners’ evaluation. Urology. 2010;75(6):1358–1363.
    1. Hellstrom WJ, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol. 2008;53:1058–1065.
    1. Beasley CM, Jr, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol. 2005;46:678–687.
    1. Guillaume M, Lonsdale F, Darstein C, Jimenez MC, Mitchell MI. Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. J Clin Pharmacol. 2007;47:1303–1310.
    1. Kloner RA, et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol. 2006;97:1778–1784.
    1. Okuyucu EE, et al. EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. Neurol Res. 2009;31:313–315.
    1. Demchenko IT, Ruehle A, Allen BW, Vann RD, Piantadosi CA. Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen. J Appl Physiol. 2009;106:1234–1242.
    1. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology. Laryngoscope. 2009;119:1586–1589.
    1. Hong BN, Yi TH, Kim SY, Kang TH. High dosage sildenafil induces hearing impairment in mice. Biol Pharm Bull. 2008;31:1981–1984.
    1. Okuyucu S, Guven OE, Akoglu E, Ucar E, Dagli S. Effect of phosphodiesterase-5 inhibitor on hearing. J Laryngol Otol. 2009;123:718–722.
    1. Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009;6:415–427.
    1. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009;6:2032–2038.
    1. Montorsi F, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924–931.
    1. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101:1279–1283.
    1. Padma-Nathan H, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479–486.
    1. Albersen M, Joniau S, Claes H, Van Poppel H. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. Adv Urol. 2008;594868
    1. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008;18:613–620.
    1. Walker DK, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297–310.
    1. Vignozzi L, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3:419–431.
    1. Kovanecz I, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008;101:203–210.
    1. Aversa A, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19:200–207.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren